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O B J E C T I V E S This study sought to determine whether regadenoson induces left ventricular
perfusion defects of similar size and severity as seen with adenosine stress.
B A C KG ROUND Total and ischemic left ventricular perfusion defect size predict patient outcome.
Therefore, it is important to show that newer stressor agents induce similar perfusion abnormalities as
observed with currently available ones.
METHOD S The ADVANCE MPI 2 (Adenosine versus Regadenoson Comparative Evaluation for
Myocardial Perfusion Imaging) study was a prospective, double-blind, randomized trial comparing image
results in patients undergoing standard gated adenosine single-photon emission computed tomogra-
phy (SPECT) myocardial perfusion imaging who were then randomized in a 2:1 ratio to either
regadenoson (N  495) or a second adenosine SPECT (N  260). Quantitative SPECT analysis was used
to determine total left ventricular perfusion defect size and the extent of ischemia. Quantiﬁcation was
performed by a single observer who was blinded to randomization and image sequence.
R E S U L T S Baseline gated perfusion results were similar in patients randomized to adenosine or
regadenoson. No signiﬁcant differences in total (11.5  15.7 vs. 11.4  15.8, p  0.88) or ischemic (4.8
 9.2 vs. 4.6  8.9, p  0.43) perfusion defect sizes were observed between the regadenoson and
adenosine groups, respectively. Linear regression showed a close correlation between adenosine and
regadenoson for total (r  0.97, p  0.001) and ischemic (r  0.95, p  0.001) left ventricular perfusion
defects. Serial differences in total (0.03  3.89 vs. 0.13  4.16, p  0.73) and ischemic (0.15  4.08
vs. 0.25  3.81, p  0.74) perfusion defect size and left ventricular ejection fraction (0.12  0.32 vs. 0.15
 0.35, p 0.27) from study 1 to study 2 were virtually identical in patients randomized to regadenoson
versus adenosine, respectively. The good correlation between serial adenosine and regadenoson studies
regarding total (0.41  5.43 vs. 0.21  5.23, p  0.76) and ischemic (0.17  5.31 vs. 0.23  6.08, p 
0.94) perfusion defects persisted in the subgroup of 308 patients with an abnormal baseline SPECT.
CONC L U S I O N S Applying quantitative analysis, regadenoson induces virtually identical scinti-
graphic results as adenosine regarding the size and severity of left ventricular perfusion defects and the
extent of scintigraphic ischemia. (J Am Coll Cardiol Img 2009;2:959–68) © 2009 by the American
College of Cardiology Foundation
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960tress single-photon emission computed to-
mography (SPECT) myocardial perfusion
imaging is widely used to diagnose (1) and to
risk stratify (2) patients with suspected or
nown coronary artery disease based on the presence
nd extent of left ventricular (LV) perfusion defects
1,2), the extent of inducible ischemia (2,3), and the
V ejection fraction (EF) (4). The value of SPECT in
hese arenas has been shown using exercise or phar-
acologic stressor modalities (2) and across patient
opulations at varying clinical risk, including those
fter infarction (5).
In this regard, it is essential that any newly
ntroduced stressor agent be shown to induce sim-
lar perfusion and functional results as observed
ith more traditional ones. Quantitative SPECT
echniques afford such accurate comparisons (6,7).
n this substudy analysis of the ADVANCE MPI 2
Adenosine versus Regadenoson Comparative
valuation for Myocardial Perfusion Imaging) trial
(8), we report the quantitative perfusion
results for regadenoson, a selective A2A
adenosine receptor agonist, as compared
with those observed with the widely used
nonselective pharmacologic vasodilator,
adenosine. A quantitative approach was
taken to better characterize the similarity
in perfusion results observed between
adenosine and regadenoson over the visual
assessment used in the original study de-
sign (8).
M E T H O D S
tudy design. The ADVANCE MPI 2 trial was a
ouble-blind, randomized trial assessing the
trength of agreement between sequential adenosi-
e–regadenoson and adenosine–adenosine SPECT
ased on visual interpretation of the image data.
he study design and main trial results are pub-
ished (8). Patients referred for a clinically indicated
harmacologic stress SPECT study were eligible for
nrollment. Exclusion criteria included contraindi-
ations to adenosine, recent acute coronary syn-
rome (3 months) or coronary revascularization
6 months), severe valvular abnormalities, and
emodynamic instability (8). Contraindications to
denosine were: greater than 1st degree atrioven-
ricular block, sick sinus syndrome in patients with-
ut a functioning artificial pacemaker, symptomatic
radycardia or high-degree atrioventricular block
n the initial study, known or suspected bronchos-
core
ssionastic lung disease, known hypersensitivity to adeno- wine, dipyridamole use within 30 h, and methylxan-
hine consumption within 12 h.
After the initial unblinded adenosine study, a
econd blinded study was performed within 4 weeks
n patients who had no changes in their clinical
tatus or cardiac medications. Before the second
tudy, patients were randomized in a 2:1 fashion to
eceive either regadenoson or adenosine stress. Im-
ges were acquired according to American Society
f Nuclear Cardiology guidelines using either 1- or
-day (depending on body weight) technetium-
9m tracer protocols or a dual-isotope (rest thal-
ium–stress technetium-99m tracer) protocol (9).
nvestigators were blinded to vasodilator random-
zation by using a double-delivery technique in
hich each patient received both a 6-min infusion
f adenosine or placebo through one intravenous
ine and a regadenoson or placebo bolus through a
econd intravenous line placed in the other arm.
Images were available for analysis in 755 of the 784
atients enrolled in the ADVANCE MPI 2 study
96%), of whom 260 were randomized to adenosine
nd 495 to regadenoson. In 29 patients the raw data
PECT images could not be obtained from the
uclear core laboratory. Both image sets could be
nalyzed in all 260 patients randomized to adenosine
nd in 493 of 495 patients randomized to regadeno-
on. In the latter 2 patients, the studies could not be
rocessed because of technical difficulties.
PECT analysis. All raw data of gated SPECT im-
ges (2 sets per patient) were electronically trans-
erred to the Methodist DeBakey Heart and Vas-
ular Center for analysis, where they were
econstructed by a single observer using standard
ack projection and identical filtering (Butterworth
lter with a critical frequency of 0.4 cycles/s, order
) (10). Motion correction was applied before
mage reconstruction if 1 pixel of x or y axis
eviation was observed over the 180° acquisition.
Images were reoriented according to American
ociety of Nuclear Cardiology guidelines (9) and
hen visually assessed in all 3 standard projections,
long with the gated SPECT and raw image data,
o assess for image quality and study normalcy/
bnormalcy. The study quality of each image set
as graded as good, fair, or poor based on the
resence of attenuation artifacts, patient motion
uring study acquisition, and extracardiac tracer
ptake interfering with image interpretation. Visual
nterpretation of all SPECT studies was performed
y one investigator (J.J.M.) and solely to allow
omparison of quantified SPECT data obtainedB B R E V I A T I O N S
N D A C R O N YM S
F ejection fraction
V left ventricular
DS perfusion defect size
DS summed difference s
PECT single-photon emi
omputed tomography
RS summed rest scoreith the 2 vasodilator agents in the subgroup of
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961atients with an initially abnormal baseline adeno-
ine study result. All references to SPECT abnor-
alcy are based on visual interpretation and not on
he quantitative results.
Quantitative SPECT was performed using a
reviously validated automated program that deter-
ines the extent and severity of the stress-induced
V perfusion defect size (PDS) and the extent of
cintigraphic scar and ischemia based on polar plot
nalysis (5). The LV defect severity within abnor-
ally perfused regions of the patient’s polar plot
as defined on a pixel-by-pixel basis as mild,
oderate, or severe based on its relation to expected
ormal pixel count activity in the normal database
olar plot (50%, 26% to 50%, and 0% to 25%,
espectively). The number of pixels falling into each
f these 3 categories was then summed to determine
he percentage of the LV with a mild, moderate, or
evere defect. Ischemia severity was calculated as
he percent count improvement toward normal
alues within ischemic pixels and defined as mini-
al (0% to 25%), moderate (26% to 50%), or
arked (50%) improvement. Thus, if a pixel had
stress value of 20 and a rest value of 70, and the
orresponding pixel in the normal database had a
alue of 80, the ischemia severity would be [(70 
0)/(80  20)] or 83% (i.e., marked improvement).
he number of pixels falling into each of these 3
ategories was then summed to determine the
ercentage of the LV with minimal, moderate, or
arked ischemia. Our quantitative program has
een shown to be reproducible for assessing serial
ifferences in myocardial perfusion (6,10) and ac-
urate in risk stratification (5,11) and is currently
ncorporated within the 4DM-SPECT software
latform. LVEF and cardiac volumes were calcu-
ated from gated SPECT images using standard
DM-SPECT software (12). Quantification was
erformed by one individual (J.J.M.) who was
linded to patient randomization and image se-
uence. The value quantified for each SPECT
ariable was used in the analysis regardless of
hether or not the study was interpreted as normal
rom a visual perspective.
tatistical analysis. The primary end point of this
ubstudy was to determine whether serial differ-
nces in total and ischemic (reversible) LV PDS
ere similar between the adenosine–regadenoson
nd adenosine–adenosine studies. Based on a sam-
le size of 758 patients, the study had 94% power to
etect a small (0.9%) absolute difference in the
hange in LV PDS between serial adenosine–
denosine and adenosine–regadenoson studies at an tlpha  0.05, and assuming a standard deviation
f 3.5.
All statistical analyses were carried out in SAS
ersion 9.1 (SAS Institute Inc., Cary, North Caro-
ina) on an XP-PRO platform (Microsoft Corp.,
edmond, Washington). Data were collected in
ccess (Microsoft Corp.), and then exported to an
AS dataset (SAS Institute Inc.); all personal in-
ormation was removed from the dataset in com-
liance with Health Insurance Portability and Ac-
ountability Act regulations. Secondary analyses
ssessed differences in total and ischemic PDS
everities and functional parameters (i.e., cardiac
olumes and LVEF) between the 2 randomized
roups using unpaired t tests. Scintigraphic differ-
nces on the baseline adenosine studies in the 2
roups were assessed using unpaired t tests. Linear
egression analysis was used to quantitate the rela-
ionship between adenosine- and regadenoson-
nduced scintigraphic variables. Mean differences,
tandard deviations, and 95% confidence intervals
ere calculated. Chi-square analysis was used to
ompare discrete variables. A p value 0.05 was
onsidered significant.
E S U L T S
tudy quality and visual interpretation. Study quality
as similar on serial adenosine–adenosine and ad-
nosine–regadenoson image sets with both sets
cored as good to excellent (175 or 67% vs. 361 or
3%); 1 good, 1 fair (26 or 10% vs. 43 or 9%); both
air (35 or 13% vs. 52 or 10%), or both poor (24 or
0% vs. 40 or 8%), respectively (p  NS).
The baseline adenosine SPECT results for the 2
andomized groups are shown in Table 1. A similar
ercentage of patients randomized to adenosine or
egadenoson had an initial adenosine study that was
isually interpreted as normal with approximately
0% of patients in each group having clearly abnor-
al perfusion results.
Serial imaging results based on visual interpreta-
ion are shown in Table 2. The overall agreement
etween adenosine–adenosine and adenosine–
egadenoson image sets was comparable (247 of
60, 95% vs. 481 of 493, 97.5%, p  NS) with a
imilar percentage of patients randomized to aden-
sine or regadenoson showing abnormal perfusion
n both SPECT studies (100 of 104, 96% vs. 202 of
04, 99%, p  NS).
Most (94.1%) of the baseline studies visually
nterpreted as normal were also normal by quanti-
ative analysis (i.e., 3% total PDS) in both the
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962denosine (134 of 144, 93.1%) and the regadenoson
251 of 265, 94.7%) groups. Conversely, most
98.7%) of the baseline studies visually interpreted
s abnormal were also abnormal by quantitative
nalysis in the adenosine (102 of 104, 98%) and
egadenoson (202 of 204, 99%) groups.
verall quantitative SPECT results. The baseline
uantitative adenosine SPECT results for the 2
nosine Scintigraphic Results
Adenosine Group
(N  260)
Regadenoson Group
(N  495) p Value
) NS
144 (55%) 266 (54%)
12 (5%) 24 (5%)
104 (40%) 205 (41%)
10.2 14.8 11.4 15.8 0.287
4.2 7.8 4.6 8.9 0.538
6.0 10.7 6.8 11.3 0.316
8.3 10.9 9.1 11.8 0.360
0%) 1.6 4.5 1.9 4.9 0.296
0.3 1.8 0.4 2.1 0.659
LV)
) 0.3 1.2 0.3 1.1 0.874
0%) 1.5 3.5 1.5 3.5 0.903
2.4 4.8 2.8 6.1 0.412
es*
64.2 13.7 63.2 15.7 0.409
117.4 58.5 118.3 61.0 0.854
47.8 44.2 51.2 52.6 0.386
; 488 regadenoson group.
e; EF  ejection fraction; ESV  end-systolic volume; LV  left ventricular; NS 
sion defect size; SPECT  single-photon emission computed tomography.
isual Interpretation Results
Normal Probably Normal Abnormal Total
Adenosine 2
1
140 (97.2%) 1 (0.7%) 3 (2.1%) 144
normal 3 (25%) 7 (58.3%) 2 (16.7%) 12
al 4 (3.9%) 0 100 (96.1) 104
147 (56.5%) 8 (3.1%) 105 (40.4%) 260
Regadenoson
1
261 (98.5%) 0 4 (1.5%) 265
normal 5 (20.8%) 18 (75%) 1 (4.2%) 24
al 2 (1.0%) 0 202 (99.0%) 204
268 (54.4%) 18 (3.6%) 207 (42.0%) 493
etween adenosine 1 and adenosine 2 studies: 247 of 260 95% and adenosinegenoson studies: 481 of 493  97.5%.andomized groups were similar (Table 1). The
verall total LV PDS was relatively small at approx-
mately 11% of the myocardium, but this increased
ignificantly when analysis was restricted to the 40%
f patients with a visually abnormal study (adeno-
ine group total PDS: 23.4  15.5 %LV; regade-
oson group total PDS: 25.7  15.5 %LV). Like-
ise, the baseline ischemic PDS increased from
.2  7.8% to 10.0  9.7% (adenosine group) and
rom 4.6  8.9% to 10.8  11.3% (regadenoson
roup) when only patients with visually abnormal
tudies were considered.
The differences in quantified SPECT variables
rom the baseline adenosine study to the regadeno-
on study are shown in Table 3. No significant
ifferences in serial LV perfusion results were ob-
erved when regadenoson became the vasodilator.
ignificant but only minor differences in LVEF and
nd-systolic volume were observed between the 2
asodilators. Linear regression analysis likewise
howed a strong relationship between serial ad-
nosine–regadenoson studies for total (r  0.97,
 0.001) (Fig. 1A), ischemia (r  0.95, p 
.001) (Fig. 1B), and scar (r  0.96, p  0.001)
efect sizes and also LVEF (r  0.99, p  0.001).
The primary end point of this study was to
etermine whether sequential serial differences in
tress-induced total and ischemic PDS could be
dentified between the 2 randomized groups. As
hown in Table 4, there were no significant differ-
nces in any of the perfusion or gated SPECT
ariables between serial adenosine versus adeno-
ine–regadenoson studies.
We have previously reported that a9% absolute
erial difference in total LV PDS represents the
5% confidence interval for a real patient change
eyond variability (6). Consistent with the mean
roup findings, only a small and similar percentage
f patients exceeded these limits when comparing
erial adenosine (12 of 260 or 4.6%) versus adeno-
ine–regadenoson (17 of 493 or 3.5%) LV PDS
maging results. Most patients randomized to aden-
sine or regadenoson had either no difference in
heir total PDS on serial imaging (102 or 39% vs.
11 or 43%, p  NS) or a 5% absolute difference
232 of 260 or 89% vs. 448 of 493 or 91%, pNS).
n both randomized groups, serial differences in
otal and ischemic PDS showed a typical Gaussian
istribution (shown for regadenoson group) (Fig. 2).
uantiﬁed SPECT results in patients with an initially
bnormal adenosine SPECT. A separate analysis was
erformed on the 308 patients (104 adenosineTable 1. Baseline Ade
Visual interpretation (%
Normal
Probably normal
Abnormal
Quantitative analysis
PDS (% LV)
Total
Ischemia
Scar
PDS severity (% LV)
Mild (50%)
Moderate (26%–5
Severe (0%–25%)
Ischemia severity (%
Minimal (0%–25%
Moderate (26%–5
Marked (50%)
Gated SPECT variabl
LVEF (%)
LV EDV (ml)
LV ESV (ml)
*n  259 adenosine group
EDV  end-diastolic volumTable 2. V
Adenosine
Normal
Probably
Abnorm
Total
Adenosine
Normal
Probably
Abnorm
Total
Agreement broup, 204 regadenoson group) who had a visually
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963bnormal baseline adenosine SPECT study. Most
f these patients by quantitative analysis had a5%
aseline ischemic perfusion defect in both the
denosine (65 or 63%) and regadenoson (134 or
6%, p  NS) groups. The total and ischemic PDS
id not differ significantly from study 1 to study 2
or the entire cohort or in either of the randomized
roups (Fig. 3). As in the overall analysis, no
ignificant differences in any of the imaging results
ere observed between the patients randomized to
erial adenosine versus adenosine–regadenoson im-
ging (Table 4). The individual patient results
ikewise show that few had a 9% absolute differ-
nce in total PDS with serial imaging in either
he adenosine–adenosine (7.7%) or adenosine–
egadenoson (5.9%) randomized groups. A repre-
entative patient example is shown in Figure 4.
I S C U S S I O N
tress SPECT is known to predict outcome across
he entire spectrum of patients with suspected or
nown coronary artery disease based on the size of
he stress-induced perfusion defect, the extent of
schemia, and the LVEF (2–5,11). This has been
hown using exercise stress and pharmacologic va-
odilators such as adenosine (2). Therefore, when
onsidering the introduction of a new stressor
gent, it is imperative that it not only be of similar
iagnostic accuracy but also confer the same prog-
ostic information as a standard agent.
Our results show based on an objective quanti-
ative analysis of the ADVANCE MPI 2 study
ataset that regadenoson induces virtually identical
cintigraphic results as adenosine with regard to the
ize and severity of the total LV PDS and the extent
f scintigraphic ischemia. This was true when
nalyzing mean group data or assessing serial dif-
erences in individual patients. In this regard, rega-
enoson is comparable to adenosine when used in
onjunction with gated SPECT imaging.
ationale for similar results with adenosine and rega-
enoson. The ability to increase myocardial blood
ow during stress from basal resting levels is termed
he coronary flow reserve of a vascular bed, and this
s regulated primarily at the arteriolar level (13).
ascular beds supplied by stenosed arteries will
tilize coronary flow reserve relative to stenosis
everity to maintain adequate resting blood flow.
hus, during exercise (14), and particularly with
harmacologic stress (15), coronary blood flow to
he vascular bed served by a normal artery will
ramatically increase, whereas flow distal to a ste-0
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Figure 1. Linear Regression Analysis of Serial Adenosine–Regadenoson SPECT Results
Excellent agreement is seen between the adenosine and regadenoson induced total (A) and isch-Table 3. Serial Differences in Scintigraphic Variables in Patients Randomized to
Regadenoson (N  493)
Baseline Adenosine
Study
Regadenoson
Study  p Value
PDS (% LV)
Total 11.4 15.8 11.5 15.7 0.03 3.9 0.88
Ischemia 4.6 8.9 4.8 9.2 0.15 4.1 0.43
Scar 6.8 11.3 6.7 11.1 0.12 2.6 0.31
PDS severity (% LV)
Mild (50%) 9.1 11.8 9.0 11.4 0.05 3.7 0.78
Moderate (26%–50%) 1.9 4.9 2.0 5.0 0.05 1.7 0.52
Severe (0%–25%) 0.4 2.1 0.5 2.1 0.02 0.89 0.54
Ischemia severity (% LV)
Minimal (0%–25%) 0.3 1.1 0.3 1.2 0.02 0.69 0.43
Moderate (26%–50%) 1.5 3.5 1.5 3.5 0.10 1.7 0.20
Marked (50%) 2.8 6.1 3.0 6.3 0.22 3.6 0.17
Gated SPECT variables*
LVEF (%) 63.2 15.7 62.7 15.5 0.48 3.06 0.001
LV EDV (ml) 118.3 61.0 118.6 61.2 0.86 15.6 0.222
LV ESV (ml) 51.2 52.6 52.2 53.4 1.4 10.4 0.003
*N  483 patients.emic (B) perfusion defect size (PDS) results. SPECT  single-photon emission computed tomography.
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964osed artery may change minimally because of
xhaustion of flow reserve under resting conditions.
ecause radiopharmaceutical tracer uptake is flow
ependent, the relative myocardial radionuclide
oncentration will be greater in vascular beds sup-
lied by normal versus stenosed arteries, leading to
lood flow heterogeneity and development of a
erfusion defect.
Both adenosine and regadenoson induce coro-
ary arteriolar vasodilation through activation of
he A2A adenosine receptor (15,16). However,
denosine activates all 4 adenosine receptors,
hereas regadenoson is a selective A2A receptor
Table 4. Comparison of Differences in Serial Imaging Results Be
Adenosine Group Rega
Total cohort (N  260)
∆ PDS (% LV)
Total 0.13 4.16 
Ischemia 0.25 3.81
Scar 0.11 2.14 
∆ PDS severity (% LV)
Mild (50%) 0.06 4.11
Moderate (26%–50%) 0.18 1.50 
Severe (0%–25%) 0.01 0.90 
∆ Ischemia severity (% LV)
Minimal (0%–25%) 0.06 0.86 
Moderate (26%–50%) 0.09 1.95 
Marked (50%) 0.09 2.83 
∆ Gated SPECT variables*
LVEF (%) 0.15 0.35
LV EDV (ml) 1.82 12.17 
LV ESV (ml) 1.60 7.14 
Abnormal baseline study† (N  104)
∆ PDS (% LV)
Total 0.41 5.43
Ischemia 0.17 5.31
Scar 0.58 2.61 
∆ PDS severity (% LV)
Mild (50%) 0.88 5.28
Moderate (26%–50%) 0.45 2.40 
Severe (0%–25%) 0.03 1.36 
∆ Ischemia severity (% LV)
Minimal (0%–25%) 0.16 1.36 
Moderate (26%–50%) 0.14 3.05
Marked (50%) 0.12 3.53 
∆ Gated SPECT variables‡
LVEF (%) 0.64 2.92
LV EDV (ml) 0.69 14.46 
LV ESV (ml) 1.36 9.28 
*N  259 (adenosine group); N  483 (regadenoson group). †N  104 (adeno
(regadenoson group).
Abbreviations as in Table 1.gonist that theoretically should induce coronary syperemia but limit the development of untoward
ide effects related to activation of the other recep-
ors (17). In humans, regadenoson increases myo-
ardial blood flow by more than 2.5-fold above
aseline for at least 2 min when given intravenously
s a 400-g bolus (18). This degree of hyperemia is
ess than that observed with adenosine (18), but
ufficient to discern relative regional differences in
yocardial tracer uptake (19), and long enough to
nsure maximal hyperemia during the time needed
o clear the radiopharmaceutical from the blood
ool (20). The similar quantitative results we report
n the current study with adenosine and regadeno-
en the Two Randomized Groups
oson Group  (95% Conﬁdence Interval) p Value
 493)
 3.89 0.11 (0.71 to 0.49) 0.73
 4.08 0.10 (0.50 to 0.70) 0.74
 2.63 0.01 (0.36 to 0.38) 0.96
 3.66 0.01 (0.56 to 0.59) 0.97
 1.68 0.13 (0.38 to 0.11) 0.27
 0.89 0.01 (0.12 to 0.14) 0.85
 0.69 0.04 (0.15 to 0.07) 0.55
 1.75 0.19 (0.47 to 0.08) 0.18
 3.60 0.13 (0.37 to 0.64) 0.58
 0.32 0.03 (0.02 to 0.08) 0.27
 15.57 0.95 (3.15 to 1.24) 0.36
 10.41 0.19 (1.62 to 1.23) 0.77
 204)
 5.23 0.20 (0.34 to 0.75) 0.76
 6.08 0.05 (0.62 to 0.52) 0.94
 3.51 0.15 (0.58 to 0.28) 0.67
 4.93 0.53 (0.00 to 1.06) 0.40
 2.60 0.36 (0.73 to 0.02) 0.23
 1.38 0.30 (0.25 to 0.31) 0.86
 1.07 0.10 (0.35 to 0.16) 0.53
 2.62 0.37 (0.77 to 0.02) 0.29
 5.43 0.52 (0.00 to 1.04) 0.31
 3.00 0.35 (0.07 to 0.77) 0.34
 18.97 0.36 (0.65 to 1.38) 0.85
 13.06 0.25 (0.59 to 1.08) 0.85
group); N  204 (regadenoson group). ‡N  99 (adenosine group); N  198twe
den
(N
0.03
0.15
0.12
0.05
0.05
0.02
0.02
0.10
0.22
0.12
0.87
1.41
(N
0.21
0.23
0.43
0.35
0.09
0.06
0.06
0.23
0.40
0.29
1.05
1.61
sineon are validation of these theoretical constructs.
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965ources of variability in serial imaging. In clinical
rials assessing patients with serial imaging, there
re several sources of variability that need to be
ecognized and potentially avoided. The inherent
atient biological variability is usually minimized by
nrolling clinically stable patients who are reimaged
ithin a relatively short time interval and in whom
hanges in medical and/or interventional anti-
schemic therapies have not occurred between stud-
es. Variability in study acquisition parameters is
lso minimized by serially using the same radio-
harmaceutical (at similar doses) and an identical
maging protocol. The previously mentioned
ources of variability are generally controlled for in
linical trials, as was true in the ADVANCE MPI
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Figure 2. Absolute Differences in Serial Imaging Results
Shown are differences () in total perfusion defect size (PDS) (A) an
regadenoson study. The differences reﬂect a typical Gaussian distrib
with regadenoson; NL  normal.trial (8). Finally, there is interpreter variability in wisually assessing serial perfusion scans, which is the
ajor source of disagreement and heterogeneity in
maging results. Currently, visual assessment of
PECT is most commonly used in clinical trials to
etermine the comparability of diagnostic informa-
ion obtained with differing acquisition protocols,
sotopes, and/or stressors. Visual assessment usually
ncludes review of the raw image data for potential
rtifacts followed by a semiquantitative segmental
nalysis of the images to generate a summed stress
core (SSS), summed rest score (SRS), and summed
ifference score (SDS). Because of the inherent
ethod of creating these scores from a 17-segment
natomic model, significant variability is inevitable.
ith quantitative analysis, the variability associated
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966aking these techniques more reproducible (6) and
herefore better suited for assessing serial changes
fter administration of differing tracers and/or stres-
ors or after treatment with anti-ischemic therapies
7). A recent editorial underscored the limitations
Ischemia
PDS
10.5
±
10.8
10.8
±
11.0
Ischemia
PDS
10.0
±
9.7
10.2
±
9.8
Ischemia
PDS
ohort
308)
Adenosine Group
(N = 104)
Regadenoson Group
(N = 204)
10.8
±
11.3
11.0
±
11.6
Total PDS
23.4
±
15.5
23.1
±
16.9
Total PDS
25.7
±
15.5
25.5
±
15.4
	

	 
ic Results in Patients With a Visually Abnormal Baseline
ischemic left ventricular (LV) perfusion defect size (PDS) results are
ohort and the 2 randomized groups. p  not signiﬁcant, all com-
dy 2.
Figure 4. Representative Patient Example
The reoriented adenosine, regadenoson, and rest images are displa
maps for adenosine and regadenoson both show a total perfusion
ischemia (regadenoson) (green).f visual assessments and the potential benefit of
uantification to add objectivity when serially ana-
yzing imaging studies (21).
mportance of quantitative analysis. In the AD-
ANCE MPI 2 trial, the primary end point was
greement by visual analysis of 3 independent
eaders for detecting 3 categories of ischemia (i.e.,
one to minimal, small to moderate, large) in
atients undergoing serial adenosine versus ad-
nosine–regadenoson imaging (8). Although agree-
ent regarding the presence and absence of isch-
mia in serial images was comparably high between
he groups (82%), there was significant heterogene-
ty in both randomized groups regarding perfusion
efect extent (i.e., SSS) and the degree of scinti-
raphic ischemia (i.e., SDS) (22). In the combined
DVANCE MPI 1 and 2 studies, the overall
isual agreement based on ischemia categories
rom study 1 to study 2 was comparably low at
2% (adenosine–adenosine) and 63% (adenosine–
egadenoson) (p  NS) (22). Agreement between
erial images worsened with increasing extent of
schemia on the baseline study in both groups.
hus, although visual analysis can be used to assess
he relative diagnostic accuracy of serial SPECT
in the short, vertical long, and horizontal long axes. The polar
ct size (PDS) of 40% with 27% ischemia (adenosine) and 25%PD
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967ased on broad categories of normalcy versus ab-
ormalcy or ischemia, this may become problematic
hen assessing prognosis because of potentially
arge serial differences in the visually estimated PDS
nd extent residual ischemia.
Our quantitative analysis of the ADVANCE
PI 2 data shows significantly better agreement
etween serial adenosine and adenosine–regadenoson
maging variables than reported in the same patients
sing visual analysis (22). The correlation coeffi-
ients we report for total (r  0.97, p  0.001) and
schemic (r  0.95, p  0.001) PDS on serial
denosine–regadenoson studies were considerably
igher than those reported for SSS (r  0.87, p 
.001) and SDS (r  0.64, p  0.001) when using
isual analysis (22).
By quantitative analysis, the mean differences
n perfusion results between serial adenosine–
denosine and adenosine–regadenoson studies were
ominal for the primary end point variables of total
0.13  4.2% vs. 0.03  3.9%), p  0.73) and
schemic (0.25  3.8% vs. 0.15  4.1%, p  0.74)
efect sizes, respectively. This was also true when
nly the 308 patients with clearly abnormal baseline
denosine studies were considered, in whom the
argest degree of variability in serial imaging would
e expected. Furthermore, over 90% of patients1999;100:1035–42. boboye OO, et al.,ifference in their defect size from the first to the
econd study. In this regard, our results are not only
onsistent with, but solidify, the results observed in
he main ADVANCE MPI 2 study.
tudy limitations. The main limitation of this study
as the large number (60%) of normal SPECT
tudies in both randomized groups. However, the
08 patients with abnormal baseline SPECT results
epresents the largest published series to date as-
essing 2 vasodilator agents when using quantitative
echniques to analyze serial differences in SPECT
esults. Quantitative analysis in the abnormal pa-
ients showed minimal differences in adenosine–
egadenoson results despite an anticipated greater
isparity in serial images due to the larger baseline
erfusion defect.
O N C L U S I O N S
pplying quantitative analysis, regadenoson in-
uces virtually identical scintigraphic results as
denosine with regard to the size and severity of LV
DS and the extent of scintigraphic ischemia.
eprint requests and correspondence: Dr. John J. Mah-
arian, Methodist DeBakey Heart and Vascular Center,
550 Fannin Street, Suite 677, Houston, Texas 77030.
andomized to either group had a 5% absolute E-mail: jmahmarian@tmhs.org.1
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